NovoCure Limited (NVCR) Stock Price & Analysis
NovoCure Limited (NVCR) closed at USD 15.1 on Thursday, October 22, 2026, down 3.14% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 15.59; the Oct 22, 2026 session ranged USD 14.94–15.66 on volume of 1,059,796 shares. Market capitalization is $1.76B, with a 52-week range of USD 9.82–21.45 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:38 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NVCR.md
Key facts (NVCR)
- Last four reported quarters (through Jun 30, 2026): revenue $699M, net income -$149M (-21.2% margin), free cash flow -$25.4M (SEC filings).
- Insider open-market sales, last ~7 months: 8 Form 4 filings, $940K; 8 not under a Rule 10b5-1 plan ($940K); 0 by opportunistic insiders, 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.29 on a 1–5 scale) (7 analysts), mean target USD 26.86 (range 17–52).
- Total return with dividends: 1Y +8.5% vs S&P 500 +14.9%; 5Y -87.5% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD -0.23, revenue estimate $182M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NVCR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $535M | $538M | $509M | $605M | $655M | $699M |
| Gross profit | $420M | $423M | $381M | $468M | $488M | — |
| Operating income | -$44.3M | -$89.5M | -$233M | -$170M | -$154M | -$154M |
| Net income | -$58.4M | -$92.5M | -$207M | -$169M | -$136M | -$149M |
| EPS (diluted) | -$0.56 | -$0.88 | -$1.95 | -$1.56 | -$1.22 | — |
| Free cash flow | $58.6M | $9.4M | -$100M | -$69.2M | -$75.7M | -$25.4M |
| Gross margin | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% | — |
| Operating margin | -8.3% | -16.6% | -45.7% | -28.2% | -23.5% | -22.1% |
| Net margin | -10.9% | -17.2% | -40.6% | -27.9% | -20.8% | -21.2% |
| Revenue growth | +8.2% | +0.5% | -5.3% | +18.8% | +8.3% | — |
| Cash + short-term investments | $209M | $115M | $241M | $164M | $93.5M | — |
| Total debt | $562M | $566M | $569M | $97.3M | $195M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NVCR)
P/S 2.5x · P/B 5.2x · FCF yield -1.45% · Earnings yield -8.45%
Insider sales (SEC Form 4, open-market, last ~7 months) (NVCR)
0 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | Leonard Frank X | Chief Executive Officer | 34,273 | $615K | 6.9% | No | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-06-02 | Leung Gabriel | Director | 2,945 | $46K | 3.2% | No | Too little history (no open-market trades in 2023) |
| 2026-06-02 | Stafford Kristin | Director | 2,945 | $46K | 20.6% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-02 | Ocean Allyson J | Director | 2,945 | $46K | 20.6% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-02 | Scannell Timothy J | Director | 2,945 | $46K | 17.1% | No | Too little history (no open-market trades in 2023) |
| 2026-06-02 | Hilleman Jeryl L | Director | 2,945 | $46K | 17.5% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-02 | Vernon W Anthony | Director | 2,945 | $46K | 1.5% | No | Too little history (no open-market trades in 2023) |
| 2026-06-02 | Hung David | Director | 2,945 | $46K | 12.6% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (NVCR)
Consensus Buy (mean 2.29 on a 1–5 scale), 7 analysts; mean target USD 26.86 (low 17, high 52).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-24 | Wedbush | Target raised | Neutral | $18 → $20 |
| 2026-07-23 | HC Wainwright & Co. | Target raised | Buy | $46 → $52 |
Total return (dividends reinvested) (NVCR)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +8.5% | -87.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +8.5% | -34.0% |
| Volatility (annualized) | 77.5% | 74.3% |
| Max drawdown | -32.5% (Jan 2026→Feb 2026) | -91.6% (Oct 2021→Feb 2026) |
NVCR revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $103.0M | 56.1% | +9.2% |
| International markets - Total | $74.7M | 40.7% | +24.6% |
| — Germany (part of International markets - Total) | $23.3M | 12.7% | +22.4% |
| — France (part of International markets - Total) | $21.3M | 11.6% | +15.9% |
| — Other international markets (part of International markets - Total) | $18.2M | 9.9% | +40.3% |
| — Japan (part of International markets - Total) | $11.8M | 6.4% | +24.2% |
| Greater China | $6.0M | 3.2% | +29.7% |
| Total revenue | $183.6M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
NVCR suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Merck (MRK) | “KEYNOTE D58 was designed and is being conducted as part of a clinical collaboration between Novocure and MSD, a tradename of Merck & Co., Inc. KEYNOTE D58 is currently open and enrolling, and we anticipate completing enrollment by the end of 2026.” |
Quoted from the company's 10-K filed Feb 26, 2026.
Companies that name NVCR in their SEC reports
| Relationship to NVCR | Company | Filing | Sentence |
|---|---|---|---|
| customer | Zai Lab Ltd (ZLAB) | 10-K Feb 26, 2026 | “For example, we source VYVGART and VYVGART Hytrulo from argenx, OPTUNE from NovoCure, QINLOCK from Deciphera, XACDURO from Innoviva, AUGTYRO from BMS, and TIVDAK from Pfizer.” |
NVCR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.23 | $-0.33 | -28.2% | $182.2M | 7 |
| Next quarter (ends Dec 2026) | $-0.24 | $-0.32 | -23.5% | $185.7M | 6 |
| Current fiscal year (ends Dec 2026) | $-1.24 | $-1.59 | -22.5% | $726.1M | 7 |
| Next fiscal year (ends Dec 2027) | $-0.81 | $-1.19 | -32.4% | $804.8M | 7 |
Key Statistics (as of October 23, 2026 at 10:38 UTC)
| Price | USD 15.1 |
|---|---|
| Change | ▼ 3.14% (down) |
| Previous Close | USD 15.59 |
| Open | USD 15.55 |
| Day Range | USD 14.94 – 15.66 |
| 52-Week Range | USD 9.82 – 21.45 |
| Volume | 1,059,796 shares |
| Market Cap | $1.76B |
| Exchange | NMS |
Technical Analysis (NVCR)
Nexqual's technical model rates NVCR "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 10:38 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.03 (neutral) |
| vs SMA50 | Below (USD 16.21) |
| MACD | -0.32 (negative) |
Analyst Ratings (NVCR)
Wall Street analysts rate NVCR "Buy" based on 7 analysts, with a mean price target of USD 26.86 (range USD 17–52), per Nexqual as of October 23, 2026 at 10:38 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 26.86 |
| High Target | USD 52 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 4 / 3 / 0 |
Earnings (NVCR)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $182.23M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.33 ▲ beat |
| 2026-03-31 | USD -0.62 vs est -0.51 ▼ miss |
| 2025-12-31 | USD -0.22 vs est -0.41 ▲ beat |
| 2025-09-30 | USD -0.33 vs est -0.42 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financials & Fundamentals (NVCR)
| Total Revenue | $699.19M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +15.60% |
| Gross Margin | +76.37% |
| Operating Margin | -5.75% |
| Profit Margin | -21.25% |
| ROE | -43.22% |
| Debt / Equity | 0.69 |
| Current Ratio | 2.89 |
| Total Cash | $440.56M |
| Total Debt | $233.42M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$25.43M (-3.6% of revenue) |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financial Health Score (NVCR)
Nexqual rates NovoCure Limited's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:38 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 76%, operating -6% (last 12 months) |
| Balance Sheet | Strong — $94M cash and investments vs $195M debt (Dec 2025, SEC) |
| Cash Flow | Weak — FCF negative: -$25M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -43%, ROA -9.3% |
Ownership (NVCR)
| Insider Ownership | +9.96% |
|---|---|
| Institutional Ownership | +90.79% |
| Shares Outstanding | 116.45M |
| Float | 96.42M |
| Short % of Float | +12.96% |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Leadership (NVCR)
NovoCure Limited is led by Frank Leonard, CEO & Director, per Nexqual as of October 23, 2026 at 10:38 UTC.
| CEO & Director | Frank Leonard |
|---|---|
| Executive Chairman | William F. Doyle |
| Chief Financial Officer | Christoph Brackmann |
| Chief Operating Officer | Mukund Paravasthu |
Major Backers & Investors (NVCR)
Notable institutional backers of NovoCure Limited include FMR, LLC, Fidelity, Soleus Capital Management, L.P., according to Nexqual as of October 23, 2026 at 10:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.92% |
| Fidelity | 8.87% |
| Soleus Capital Management, L.P. | 8.51% |
| Morgan Stanley | 3.88% |
| Wells Fargo & Company | 2.17% |
| Quantinno Capital Management, LP | 1.91% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.52% |
| Vanguard Group | 9.6% |
| State Street | 2.46% |
| Geode Capital | 2.4% |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
From NovoCure Limited's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We are subject to announced and unannounced inspections by the FDA to determine our compliance with the Quality System Regulation ("QSR") and other regulations and these inspections include the manufacturing facilities of our suppliers.
- Clinical studies must be conducted under the oversight of an IRB for the relevant clinical study sites and must comply with FDA regulations, including those relating to current Good Clinical Practices ("cGCPs").
- Clinical studies involving pharmacological/immunological therapy candidates may be regulated under FDA's drug regulations, Unless exempt, such studies require authorization from FDA of an Investigational New Drug Application ("IND") for a specified number of patients and study sites.
- We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells.
Partnerships
- In 2022, we announced the final results from our EF-31 Phase 2 study, a single-arm study evaluating the safety and efficacy of TTFields therapy use together with XELOX chemotherapy (and trastuzumab for HER2-positive patients) as first-line treatment for adult patients diagnosed with unresectable gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in partnership with Zai.
- Pursuant to our strategic collaboration with Zai, we granted Zai a license to commercialize TTFields therapy in Greater China.
Legal & Regulatory Risks (Item 1A, quoted)
- Our device candidates must undergo rigorous preclinical and clinical testing and we must obtain regulatory approvals, which could be costly and time-consuming and subject us to unanticipated delays or prevent us from marketing any devices.
- We may choose to, or may be required to, suspend, repeat or terminate our clinical studies if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the studies are not well designed.
- We pay taxes, including tariffs, in multiple jurisdictions and adverse determinations by taxing or other governmental authorities or changes in tax laws, rates or our status under which tax jurisdictions apply to us could increase our tax burden or otherwise affect our financial condition or results of operations, as well as subject our shareholders to additional taxes.
- We are affected by and subject to environmental laws and regulations that could be costly to comply with or that may result in costly liabilities.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFLY | Butterfly Network, Inc. | USD 6.81 | ▼ 4.08% |
| ESTA | Establishment Labs Holdings Inc | USD 63.52 | ▲ 1.99% |
| ALMR | Alamar Biosciences, Inc. | USD 29.72 | ▼ 5.5% |
| INSP | Inspire Medical Systems, Inc. | USD 72.66 | ▲ 2.24% |
| AXGN | AxoGen, Inc. | USD 36.68 | ▲ 0.55% |
| UFPT | UFP Technologies, Inc. | USD 297.33 | ▲ 2.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:38 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt